Anthem · Tirzepatide · US health-plan appeal rights

Tirzepatide denied as not FDA-approved for this use by Anthem?

Q: How long do I have to appeal a Anthem Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Anthem typically requires

HbA1c ≥6.5% within 12 months OR existing T2DM diagnosis.

Source policy: Anthem tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Anthem angle on Tirzepatide

## Anthem's "Not FDA-Approved" Denial on Tirzepatide — Decoded

When Anthem BCBS issues a denial citing "not FDA-approved for the requested indication," the mechanic is almost never that tirzepatide itself lacks FDA approval — Mounjaro (Lilly NDA 215866, May 2022) and Zepbound (NDA 217806, Nov 2023) are both approved. The denial is an off-label use determination triggered by Anthem's Clinical Criteria CC-0021 (Glucose-Lowering Agents) when prescribed for weight management, PCOS, NAFLD, or pre-diabetes without a confirmed T2DM diagnosis, or the parallel CC-0085 (Weight Loss Agents) when Zepbound is requested but the plan excludes anti-obesity medications. Anthem routes these through CarelonRx (its in-house PBM since Jan 2024 migration off IngenioRx) — so the prior auth and appeal pathway sits at carelonrx.com/providers, not Express Scripts.

The coverage gate Anthem applies is binary: HbA1c ≥6.5% documented within the last 12 months, OR an established ICD-10 E11.x diagnosis. A missing lab or an E66.9 (obesity) code without E11 will auto-deny as off-label. The fix at Level 1 is rarely a clinical argument — it's documentary. Pull the most recent A1c, attach the ICD-10 problem list showing E11.9/E11.65, and include the chart note linking the prescription to glycemic control rather than weight loss.

Where the denial gets harder is when Anthem invokes "experimental/investigational" language. Under 29 CFR §2560.503-1(g)(1)(v), ERISA plans must disclose the specific scientific or clinical judgment underlying an E&I determination — boilerplate citations to the CC policy are insufficient. Pinto v. Aetna Life Ins. Co., 753 F.3d 1163 (10th Cir. 2014), confirms the plan administrator bears the burden of substantiating the E&I label with record evidence; vague references to "FDA labeling" without engaging the actual peer-reviewed support (SURPASS-1 through -5, SURMOUNT-1/2 for cardiometabolic endpoints) is reversible on de novo or even arbitrary-and-capricious review.

For fully-insured Anthem plans, the MHPAEA NQTL framework at 29 CFR §2590.712(c)(4) is also live when tirzepatide is denied for a comorbid eating disorder or psychiatric indication — Anthem's behavioral side is administered by Carelon Behavioral Health, and a step-therapy/PA applied more stringently to medical-side GLP-1s than to behavioral-side equivalents is a documented NQTL violation. If the appeal involves a self-funded ERISA plan, request the comparative analysis under the Consolidated Appropriations Act §203.

Tactical tip: File the Level 1 appeal through CarelonRx with three attachments — (1) the dated A1c lab, (2) the ICD-10 problem list with E11.x highlighted, and (3) a one-page prescriber letter citing CC-0021 by name and explicitly invoking 29 CFR §2560.503-1(g) to demand specific clinical rationale if denied again. This converts a soft documentation denial into a procedural-defect record for external review under your state DOI (or IRO under §2719 for ERISA).

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Anthem appeals

Other insurers on Tirzepatide

Other denial reasons for Anthem Tirzepatide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.